NR3C2 and hydrops fetalis: The study also rediscovered genes encoding targets for HF-approved drugs, including ADRB1 for beta-blockers, SCNN1A for diuretics, NR3C2 for mineralocorticoid receptor antagonists, CACNA1D for calcium channel blockers, and SLC5A2 for SGLT2 inhibitors [19].